Paper41007774
Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential.
Shatalov PA and 12 others. Biomedicines, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential. Papers, record 41007774. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007774
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References217
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33424836 | A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens. | Front Immunol | 2020 | https://conductscience.org/library/papers/33424836 | PubMed |
| 2 | 39213364 | Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. | Sci Adv | 2024 | https://conductscience.org/library/papers/39213364 | PubMed |
| 3 | 16111635 | Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. | Immunity | 2005 | https://conductscience.org/library/papers/16111635 | PubMed |
| 4 | 38803496 | Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies. | Front Immunol | 2024 | https://conductscience.org/library/papers/38803496 | PubMed |
| 5 | 27081325 | Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. | Clin Med Insights Oncol | 2016 | https://conductscience.org/library/papers/27081325 | PubMed |
| 6 | 40281786 | Comprehensive Analysis of Oncogenic Somatic Alterations of Mismatch Repair Gene in Breast Cancer Patients. | Bioengineering (Basel) | 2025 | https://conductscience.org/library/papers/40281786 | PubMed |
| 7 | 29567706 | Personalized vaccines for cancer immunotherapy. | Science | 2018 | https://conductscience.org/library/papers/29567706 | PubMed |
| 8 | 38417916 | CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/38417916 | PubMed |
| 9 | 19002680 | NetMHCpan, a method for MHC class I binding prediction beyond humans. | Immunogenetics | 2009 | https://conductscience.org/library/papers/19002680 | PubMed |
| 10 | 38503296 | FDA approval of the first cellular therapy for a solid (non-hematologic) cancer. | Mol Ther | 2024 | https://conductscience.org/library/papers/38503296 | PubMed |
| 11 | 35387130 | A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. | Front Oncol | 2022 | https://conductscience.org/library/papers/35387130 | PubMed |
| 12 | 39929822 | Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer. | NPJ Breast Cancer | 2025 | https://conductscience.org/library/papers/39929822 | PubMed |
| 13 | 29755464 | Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. | Front Immunol | 2018 | https://conductscience.org/library/papers/29755464 | PubMed |
| 14 | 36318382 | EGFR as a potent CAR T target in triple negative breast cancer brain metastases. | Breast Cancer Res Treat | 2023 | https://conductscience.org/library/papers/36318382 | PubMed |
| 15 | 39023168 | Engineered CAR-NK Cells with Tolerance to H2O2 and Hypoxia Can Suppress Postoperative Relapse of Triple-Negative Breast Cancers. | Cancer Immunol Res | 2024 | https://conductscience.org/library/papers/39023168 | PubMed |
| 16 | 22186794 | The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. | Mol Ther | 2012 | https://conductscience.org/library/papers/22186794 | PubMed |
| 17 | 31611695 | Predicting HLA class II antigen presentation through integrated deep learning. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/31611695 | PubMed |
| 18 | 36434591 | Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment. | BMC Cancer | 2022 | https://conductscience.org/library/papers/36434591 | PubMed |
| 19 | 40033418 | Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/40033418 | PubMed |
| 20 | 40574862 | Advances and challenges in neoantigen prediction for cancer immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40574862 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42846762 | Advancements in polymer-based drug delivery systems targeting the tumor microenvironment for immunotherapy of triple-negative breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42846762 | PubMed |
| 42539001 | Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer. | bioRxiv | 2026 | https://conductscience.org/library/papers/42539001 | PubMed |
| 42353619 | Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42353619 | PubMed |
| 42147479 | Triple-negative breast cancer: current understanding and future perspectives. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42147479 | PubMed |
| 42120393 | Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42120393 | PubMed |
| 42099744 | Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42099744 | PubMed |
| 42035063 | Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42035063 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007774
GET https://conductscience.org/api/papers/v1/41007774/references?page=2